+137%

est. 2Y upside i

HealthcareSeries B

We make healthcare in emerging markets affordable and accessible

Rank

#183

Sector

HealthTech

Est. Liquidity

~4Y

Data Quality

Data: Medium

Reliance Health offers high growth potential with a projected 137% expected upside in 2 years, but risks are elevated due to a stale valuation, incumbent competition, and need for additional capital.

Last updated: July 3, 2026

Bull (20%)+300%

If Reliance Health achieves breakeven and opens an IPO window, the multiple could hold at 3.5x on projected $292M ARR, but stage cap limits upside to +300%.

Base (40%)+189%

Multiple converges to 2x on $292M ARR, yielding ~189% upside after 20% dilution from a likely future raise.

Bear (40%)+4%

Multiple compresses to 1x on $292M ARR, minimal upside after dilution; preference stack protects some value but common returns are low.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

38%

Total funding $48M at 1x non-participating preferred represents 38% of current valuation, a severe overhang that could wipe out common in a down scenario.

Dilution Risk

high

With no funding since Feb 2022 and 425 employees, a down round or substantial dilution is likely within 24 months.

Secondary Liquidity

none

No secondary market activity detected; stale primary valuation suggests limited liquidity.

Questions to Ask at the Interview

Strategic questions based on Reliance Health's data — designed to show you've done your homework.

  • 1

    “How does your integrated clinic model defend against deep-pocketed incumbents like AXA?”

  • 2

    “What is the path to unit economics breakeven given the recent layoffs?”

  • 3

    “How do you value equity compensation given the stale 2022 round and potential down round risk?”

Community

Valuation Sentiment

Our model estimates +137% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.